Publications | UCSF Department of Medicine at VA

We work hard to attract, retain, and support the most outstanding faculty.

Filter by

Nature genetics

Multiple loci associated with indices of renal function and chronic kidney disease.

2009

Authors: Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Chen YD, de Boer IH, Haritunians T, Lumley T, Sarnak M, Siscovick D, Benjamin EJ, Levy D, Upadhyay A, Aulchenko YS, Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, Chasman DI, Paré G, Ridker PM, Kao WH, Witteman JC, Coresh J, Shlipak MG, Fox CS

Reproductive biology and endocrinology : RB&E | Volume 7

Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells.

2009

Authors: Goldman S, Lovett DH, Shalev E

View Abstract

BACKGROUND

Although the MMP-2 promoter lacks a canonical progesterone response element (PRE), the hormone inhibits MMP-2 expression and is part of treatment protocols in gynecological invasive pathologies, including endometriosis and endometrial hyperplasia. This study aimed to explore the mechanism by which progesterone inhibits MMP-2 expression.

METHODS

The effect of progesterone on MMP-2 expression in the JAR human choriocarcinoma cell line was analyzed by gelatin zymography. MMP-2 transcript expression was studied using Northern blot and semi-quantitative RT-PCR. Rat promoter deletion analysis, electrophoretic mobility shift and chromatin immuno-precipitation assays were performed in order to locate the DNA binding site and the transcription factors involved in MMP-2 regulation.

RESULTS

Progesterone significantly decreased secretion of pro-MMP-2 and MMP-2 transcript expression level in a dose-dependent manner. Progesterone (1 microM) significantly decreased both human and rat MMP-2 promoter activity (80.1% +/- 0.3 and 81.3% +/- 0.23, respectively). Progesterone acts through the SP1 family transcription factors-binding site, located between -1433 and -1342 bp region from the transcriptional start site of the rat MMP-2 promoter, which are present in the orthologous human MMP-2 promoter. Progesterone receptor (PR), SP2, SP3 and SP4 proteins are constitutively bound to this consensus sequence.

CONCLUSION

Progesterone reduces PR and SP4 binding to the MMP-2 promoter, thereby suppressing transcription. Progesterone also promotes SP4 degradation. These novel mechanisms of MMP-2 regulation by progesterone provide the biological rationale for the use of progesterone in clinical settings associated with increased MMP-2 expression.

View on PubMed

The New England journal of medicine

Clinical problem-solving. A red flag.

2009

Authors: Fazel R, Dhaliwal G, Saint S, Nallamothu BK

Forensic science international

Cadaveric volatile organic compounds released by decaying pig carcasses (Sus domesticus L.) in different biotopes.

2009

Authors: Dekeirsschieter J, Verheggen FJ, Gohy M, Hubrecht F, Bourguignon L, Lognay G, Haubruge E

Journal of vascular surgery

Systemic inflammation, coagulopathy, and acute renal insufficiency following endovascular thoracoabdominal aortic aneurysm repair.

2009

Authors: Chang CK, Chuter TA, Niemann CU, Shlipak MG, Cohen MJ, Reilly LM, Hiramoto JS

American journal of kidney diseases : the official journal of the National Kidney Foundation

C-reactive protein, statins, and cardiovascular risk: what can JUPITER teach us?

2009

Authors: Rogers AM, Shlipak MG

Journal of hospital medicine

The tip of the iceberg.

2009

Authors: Lieu C, Janssen WJ, Saint S, Dhaliwal G

Clinical and experimental rheumatology

Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients.

2009

Authors: Schmajuk G, Bush TM, Burkham J, Krishnan E, Chung L

Current opinion in nephrology and hypertension

Some methodological issues in studying the long-term renal sequelae of acute kidney injury.

2009

Authors: Liu KD, Lo L, Hsu CY

Menopause (New York, N.Y.) | Volume 16 of Issue 3

MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.

2009

Authors: Grady D, Sawaya GF, Johnson KC, Koltun W, Hess R, Vittinghoff E, Kristof M, Tagliaferri M, Cohen I, Ensrud KE

View Abstract

OBJECTIVE

To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes.

METHODS

A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks.

RESULTS

The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03).

CONCLUSIONS

Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.

View on PubMed